Extranodal NK-/T-cell lymphoma, nasal type

ICD-O-2 Morphology

9713/3: Angiocentric T-cell lymphoma

ICD-O-3 Morphology

9719/3: Extranodal NK/T cell lymphoma, nasal type
Effective 2001 and later


for cases diagnosed 2001 and later

Primary Site(s)

See Module 7
Most common sites of involvement: upper aerodigestive tract (nasal cavity, nasopharynx, paranasal sinuses, palate) with the nasal cavity (C300) being the prototypic site of involvement.

Abstractor Notes

Extranodal NK/T cell lymphoma almost always shows an extranodal presentation. Some cases may be accompanied by secondary LN involvement although rare instances of primary LN involvement in the absence of extranodal involvement has been reported.

Extension to adjacent tissues such as the nasopharynx, paranasal sinuses, orbit, oral cavity, palate, and oropharynx are possible. At presentation, the disease is often localized to the upper aerodigestive tract.

Disseminated involvement may have involvement of the lymph nodes, bone marrow and peripheral blood.

Diagnostic Confirmation

This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.


Not Applicable

Module Rule


Alternate Names

Angiocentric immunoproliferative lesion
Angiocentric T-cell lymphoma [OBS]
Extranasal NK/T-cell lymphoma
Lethal granuloma
Lethal midline granuloma [OBS]
Malignant midline reticulosis [OBS]
Malignant reticulosis, NOS [OBS]
Polymorphic reticulosis [OBS]


Extranodal NK-/T-cell lymphoma, nasal type, is a predominantly extranodal lymphoma of NK-cell or T-cell lineage, characterized by vascular damage and destruction, prominent necrosis, cytotoxic phenotype, and association with EBV. It is designated as NK/T-cell lymphoma because although most cases appear to be genuine NK-cell neoplasms, some cases are of cytotoxic T-cell lineage.

Definitive Diagnostic Methods

Genetic testing
Histologic confirmation

Genetics Data

IG genes are clonally rearranged
TR genes are clonally rearranged


CD2 positive
CD3 negative or epsilon positive
CD4 negative
CD5 negative
CD7 expression
CD8 negative
CD16 negative
CD30 positive
CD43 positive
CD45R0 positive
CD56 positive
CD57 negative
FASL (CD25) expressed
Granzyme B positive
Perforin negative
TIA1 positive


Hematologic Transplant and/or Endocrine Procedures
Hormone therapy
Radiation therapy

Transformations to

There are no known transformations

Transformations from

There are no known transformations

Corresponding ICD-9 Codes

202.8 Other lymphoma

Corresponding ICD-10 Codes

C84.5 Other and unspecified T-cell lymphomas

Corresponding ICD-10-CM Codes (U.S. only)

C86.0 Extranodal NK/T-cell lymphoma, nasal type (effective October 01, 2015)
C84.9 Mature T/NK-cell lymphomas, unspecified (effective October 01, 2015)

Signs and Symptoms

Drenching night sweats
Fever (for no known reason)
Midfacial destructive lesions
Nasal obstruction due to mass
Pain in the chest, abdomen, or bones (for no known reason)
Painless swelling in the lymph nodes
Ulcerated nodular skin lesions
Weight loss (for no known reason)

Diagnostic Exams

Blood chemistry studies
CT (CAT) scan
Cytogenetic analysis
Flow cytometry
Lymph node biopsy
PET (positron emission tomography) scan

Progression and Transformation


Epidemiology and Mortality

Age: more common in adults
Race: more prevalent in Asians and Native Americans
Sex: male predominance
Survival: 30-40%. Poorer survival time when occurring outside of the nasal cavity


Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Mature T- and NK-cell neoplasms
Pages: 368-371

International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes

National Cancer Institute
Section: General Information About Adult Non-Hodgkin Lymphoma (NHL)